We work with partners in a variety of ways to make the most of innovations that could deliver tangible benefits to those suffering from serious illness.
Amgen actively seeks innovations within other companies and universities that will enhance our capabilities and augment our therapeutic offerings. Although our scientists and business specialists are in constant contact with their peers, we encourage researchers to contact us with potential opportunities. We strive to ensure that your opportunity receives a prompt yet comprehensive evaluation.
Our process involves three key steps. First, our team conducts an initial evaluation of the non-confidential data you provide. Next, an integrated evaluation team examines confidential data in detail. This team may include members of your staff as well as Amgen representatives from research, manufacturing, preclinical and clinical development, sales and marketing, senior management, law, and corporate development, as appropriate. Finally, Amgen Business Development leads due diligence efforts, along with the negotiation of deal terms.
Recent transactions include spinouts, equity investments, joint ventures, early-stage partnerships, limited partnership investments, collaborations, in- and out-licensing, acquisitions, and academic partnerships.
Spinouts and Startups
Equity Investments
Joint Ventures
Early-Stage Partnerships
Limited Partnership Investments
Collaborations and Licenses
Acquisitions
Academic Partnerships